Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595738 | 0.85 | HSD17B10 (0.48) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL15255433 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10348509 | 0.80 | MAPT (0.37) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL7963299 | 0.79 | ALDH1A1 (0.34) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL10554478 | 0.78 | BRD4 (0.38) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL125826 | 0.78 | POLB (0.36) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL14867427 | 0.77 | KDM4E (0.35) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL180151 | 0.77 | POLB (0.35) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| SCHEMBL9333344 | 0.77 | KDM4E (0.35) | ALDH1A1MAPTKDM4EPOLBTSHR | |
| Calcium SCHEMBL29816288 | 0.77 | POLB (0.35) | ALDH1A1MAPTKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | claimed |
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846747-B2 | Compounds and methods for altering lifespan of eukaryotic organisms | UNIVERSITY OF ROCHESTER (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | SOUTHERN RESEARCH INSTITUTE (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | SOUTHERN RESEARCH INSTITUTE (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2011062964-A1 | COMPOUNDS AND METHODS FOR ALTERING LIFESPAN OF EUKARYOTIC ORGANISMS | UNIVERSITY OF ROCHESTER (US) | 2011-05-26 | — | — | WO | disclosed |
| US-6215016-B1 | HEMATOPOIETIC AGENTS; PREVENTING CYTOPENIA | TORAY INDUSTRIES, INC. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-0841063-A1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1998-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096175-A1 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms | HDAC5, AADAC, SIRT1 | ALDH1A1 562/4885MAPT 2167/4885KDM4E 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.